文献速递中药与中成药合理使用

舒肝宁注射液诱导三阴性乳腺癌细胞铁死亡并抑制肿瘤生长

Shuganning injection, a traditional Chinese patent medicine, induces ferroptosis and suppresses tumor growth in triple-negative breast cancer cells.
PubMed 文献 · Phytomedicine · 2021-03-18

本研究评估中成药舒肝宁注射液(SGNI)对三阴性乳腺癌(TNBC)细胞的抗癌活性并阐明其诱导铁死亡的机制。体外实验显示SGNI选择性抑制TNBC细胞增殖,其细胞死亡不依赖caspase但可被铁死亡抑制剂逆转,且依赖HO-1;体内实验证实SGNI显著抑制裸鼠移植瘤生长。

要点

  • SGNI选择性抑制TNBC细胞增殖,对非TNBC乳腺癌细胞和正常细胞影响较小。
  • SGNI诱导的TNBC细胞死亡为铁死亡,可被ferrostatin-1、liproxstatin-1等逆转。
  • SGNI诱导铁死亡依赖HO-1,敲低或抑制HO-1可减轻细胞死亡。

核心结论

  • 舒肝宁注射液通过诱导铁死亡选择性抑制三阴性乳腺癌细胞增殖并抑制移植瘤生长。

研究设计与样本

  • 体外采用细胞增殖实验,体内采用裸鼠移植瘤生长实验,通过流式检测脂质ROS、不稳定铁池及PI排除实验判定铁死亡。

主要发现

  • SGNI选择性抑制TNBC细胞增殖,其细胞死亡形态不同于凋亡且不能被泛caspase抑制剂Z-VAD(OMe)-FMK挽救。
  • SGNI诱导的细胞死亡可被ferrostatin-1、liproxstatin-1、rosiglitazone、1,10-phenanthroline和deferoxamine阻断。
  • SGNI诱导铁死亡依赖HO-1,促进细胞内不稳定铁池积累,HO-1敲低或tin protoporphyrin IX抑制可减轻。
  • SGNI显著抑制TNBC细胞系MD-MB-231在裸鼠体内的移植瘤生长。

临床怎么用

  • 舒肝宁注射液作为已上市中成药,可能为TNBC治疗提供诱导铁死亡的新方案,但需进一步临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Triple-negative breast cancer (TNBC), lacking targeted therapies currently, is susceptible to ferroptosis, a recently defined form of cell death. PURPOSE: To evaluate the anticancer activity of Shuganning injection (SGNI), a traditional Chinese patent medicine, on TNBC cells; To elucidate the mechanism of SGNI induced ferroptosis. METHODS: The anticancer activity of SGNI was examined via in vitro cell proliferation assays and in vivo xenograft growth assay. Ferroptosis was determined by flow-cytometric analysis of lipid ROS, labile iron pool measurement, and propidium iodide exclusion assay. The dependency on heme oxygenase 1 (HO-1) of SGNI induced ferroptosis was confirmed by genetic knockdown and pharmacological inhibition of the protein. RESULTS: SGNI selectively inhibited the proliferation of TNBC cells compared to non-TNBC breast cancer cells and normal cells. The cell death induced by SGNI in TNBC cells showed distinct morphology from apoptosis and could not be rescued by the pan-caspase inhibitor Z-VAD(OMe)-FMK. On the other hand, SGNI induced cell death was blocked by the lipid ROS scavengers ferrostatin-1 and liproxstatin-1, the acyl-CoA synthetase long chain family member 4 inhibitor rosiglitazone, and the iron chelators 1,10-phenanthroline and deferoxamine. These data indicated that SGNI induced a ferroptotic cell death of TNBC cells. Mechanistically, SGNI induced ferroptosis was dependent on HO-1, which promotes intracellular labile iron pool accumulation, and was alleviated by HO-1 knockdown and inhibition by tin protoporphyrin IX. In line with the in vitro data, SGNI significantly inhibited the xenograft growth of TNBC cell line MD-MB-231 in nude mice. CONCLUSION: Collectively, our study elaborates on a promising regimen for TNBC treatment through induction of ferroptosis by SGNI, a traditional Chinese patent medicine currently available in the clinic, which merits further investigation.

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Du J, Wang L, Huang X, et al. Shuganning injection, a traditional Chinese patent medicine, induces ferroptosis and suppresses tumor growth in triple-negative breast cancer cells. Phytomedicine. 2021. PMID: 33827043. doi:10.1016/j.phymed.2021.153551

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。